



News Release

Suven Life Sciences at Centrum Pharma Day Mumbai for analysts' meet

HYDERABAD, INDIA (December 14, 2015) – Suven Life Sciences is participating and presenting in Centrum Pharma analysts' meet being held at Mumbai on Dec 15, 2015.

During Centrum Pharma Day Suven be updating the investors and analysts" on Suven Life Sciences and our discovery research programs.

Suven Life Sciences Ltd, Hyderabad, a biopharmaceutical company, a successful and dividend paying company is in existence for over 26 years, involved in path breaking business model "CRAMS" (Contract Research and Manufacturing Services) offering services to global pharma companies. Revenues earned out of this business model are used for funding CNS based drug discovery and development programs for the past 10 years.

Suven discovery research programs are focused on discovering and developing novel pharmaceutical products, which are first in class or best in class CNS therapies through the use of GPCR targets. At this point of time, Suven has a pipeline of 13 compounds for 27 inventions with 750+ granted product patents, all of them focused on diseases under Central Nervous System disorders.

Suven has 3 clinical stage compounds, a Phase 2 initiated candidate SUVN-502, Phase 1 completed candidate SUVN-G3031 and Phase 1 initiated candidate SUVN-D-4010 for Alzheimer's disease and Schizophrenia. In addition, the Company has ten (10) internally-discovered therapeutic drug candidates currently in pre-clinical stage of development targeting conditions such as ADHD, dementia, depression, Huntington's disease, Parkinson's disease and pain.

For more information please visit our Web site at http://www.suven.com

Risk Statement:

Except for historical information, all of the statements, expectations and assumptions, including expectations and assumptions, contained in this news release may be forward-looking statements that involve a number of risks and uncertainties. Although Suven attempts to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based. Other important factors which could cause results to differ materially including outsourcing trends, economic conditions, dependence on collaborative partnership programs, retention of key personnel, technological advances and continued success in growth of sales that may make our products/services offerings less competitive; Suven may not undertake to update any forward-looking statements that may be made from time to time.

Suven Life Sciences Limited